292 related articles for article (PubMed ID: 37075068)
1. Nanotherapeutic Approach to Delivery of Chemo- and Gene Therapy for Organ-Confined and Advanced Castration-Resistant Prostate Cancer.
Sharma S; Mahajan SD; Chevli K; Schwartz SA; Aalinkeel R
Crit Rev Ther Drug Carrier Syst; 2023; 40(4):69-100. PubMed ID: 37075068
[TBL] [Abstract][Full Text] [Related]
2. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
3. Aptamer-Functionalized Dendrimer Delivery of Plasmid-Encoding lncRNA
Tai Z; Ma J; Ding J; Pan H; Chai R; Zhu C; Cui Z; Chen Z; Zhu Q
Int J Nanomedicine; 2020; 15():10305-10320. PubMed ID: 33376323
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction.
Lee GT; Kang DI; Ha YS; Jung YS; Chung J; Min K; Kim TH; Moon KH; Chung JM; Lee DH; Kim WJ; Kim IY
Br J Cancer; 2014 Mar; 110(6):1634-44. PubMed ID: 24518599
[TBL] [Abstract][Full Text] [Related]
5. Self-assembled albumin nanoparticles for combination therapy in prostate cancer.
Lian H; Wu J; Hu Y; Guo H
Int J Nanomedicine; 2017; 12():7777-7787. PubMed ID: 29123392
[TBL] [Abstract][Full Text] [Related]
6. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
[TBL] [Abstract][Full Text] [Related]
7. Aptamer-Conjugated Multifunctional Polymeric Nanoparticles as Cancer-Targeted, MRI-Ultrasensitive Drug Delivery Systems for Treatment of Castration-Resistant Prostate Cancer.
Fang Y; Lin S; Yang F; Situ J; Lin S; Luo Y
Biomed Res Int; 2020; 2020():9186583. PubMed ID: 32420382
[TBL] [Abstract][Full Text] [Related]
8. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
9. MiRNA 34a: a therapeutic target for castration-resistant prostate cancer.
Chalanqui MJ; O'Doherty M; Dunne NJ; McCarthy HO
Expert Opin Ther Targets; 2016 Sep; 20(9):1075-85. PubMed ID: 26942553
[TBL] [Abstract][Full Text] [Related]
10. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis.
Li S; Kang Y; Zeng Y
Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189033. PubMed ID: 38040267
[TBL] [Abstract][Full Text] [Related]
12. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.
Shi SJ; Wang LJ; Han DH; Wu JH; Jiao D; Zhang KL; Chen JW; Li Y; Yang F; Zhang JL; Zheng GX; Yang AG; Zhao AZ; Qin WJ; Wen WH
Theranostics; 2019; 9(5):1247-1263. PubMed ID: 30867828
[No Abstract] [Full Text] [Related]
14. TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression.
Baylot V; Karaki S; Rocchi P
Results Probl Cell Differ; 2017; 64():255-261. PubMed ID: 29149413
[TBL] [Abstract][Full Text] [Related]
15. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?
Baboudjian M; Gauthé M; Barret E; Brureau L; Rocchi P; Créhange G; Dariane C; Fiard G; Fromont G; Beauval JB; Mathieu R; Renard-Penna R; Roubaud G; Ruffion A; Sargos P; Rouprêt M; Ploussard G
Prog Urol; 2022 Jun; 32(6S1):6S43-6S53. PubMed ID: 36719646
[TBL] [Abstract][Full Text] [Related]
16. A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).
Yoshida S; Takahara T; Arita Y; Ito M; Hayakawa S; Oguchi T; Komai Y; Numao N; Yuasa T; Inoue M; Ushijima H; Kudo S; Shimano Y; Nakamura Y; Uchida Y; Uehara S; Tanaka H; Yaegashi H; Izumi K; Yokoyama M; Matsuoka Y; Yoshioka Y; Konishi K; Nakanishi K; Nagahara A; Hirakawa A; Koike R; Koga F; Nishimura K; Mizokami A; Yonese J; Kageyama Y; Yoshimura R; Fujii Y
BMC Urol; 2023 Mar; 23(1):33. PubMed ID: 36879257
[TBL] [Abstract][Full Text] [Related]
17. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
Mizokami A; Kadono Y; Kitagawa Y; Izumi K; Konaka H
Int J Urol; 2017 Aug; 24(8):566-572. PubMed ID: 28577511
[TBL] [Abstract][Full Text] [Related]
18. Theranostic Nanoparticles for RNA-Based Cancer Treatment.
Revia RA; Stephen ZR; Zhang M
Acc Chem Res; 2019 Jun; 52(6):1496-1506. PubMed ID: 31135134
[TBL] [Abstract][Full Text] [Related]
19. A Multimodal Theranostic Nanoformulation That Dramatically Enhances Docetaxel Efficacy Against Castration Resistant Prostate Cancer.
Bulmahn JC; Kutscher HL; Cwiklinski K; Schwartz SA; Prasad PN; Aalinkeel R
J Pharm Sci; 2020 Sep; 109(9):2874-2883. PubMed ID: 32534879
[TBL] [Abstract][Full Text] [Related]
20. Integrative exploration of the mutual gene signatures and immune microenvironment between benign prostate hyperplasia and castration-resistant prostate cancer.
Wu F; Ning H; Sun Y; Wu H; Lyu J
Aging Male; 2023 Dec; 26(1):2183947. PubMed ID: 36974949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]